glp-1 kidney outcomes news Potential protective effects of glucagon‐like peptide‐1 receptor agonists - Trevella - 2024 - Nephrology GLP-1 drugs may extend life,

It has progressed through clinical development and received EMA approval for erythropoietic protoporphyria (EPP)

On the therapeutic side, the palmitoylation inhibitor 2-bromopalmitate (2-BP) was shown to improve MASH symptoms, which provides an experimental rationale for the development of therapeutic strategies targeting palmitoylation modifications (158)

For instance, in August 2025, Viking Therapeutics, a US-based company specializing in metabolic and endocrine disorder treatments, announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial of VK2735, an investigational oral dual GLP-1/GIP agonist for obesity

These two mechanisms are not merely additive